Related Experiment Videos
Insights
Bevantolol effectively lowers diastolic blood pressure in patients with essential hypertension. This antihypertensive medication demonstrated sustained efficacy over eight weeks and was well-tolerated in clinical trials.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Essential hypertension is a prevalent cardiovascular condition requiring effective treatment.
- Antihypertensive drug efficacy and tolerability are crucial for patient management.
Purpose of the Study:
- To evaluate the antihypertensive efficacy of bevantolol at various fixed doses.
- To compare bevantolol's effectiveness against a placebo in patients with essential hypertension.
Main Methods:
- A multicenter, double-blind study involving 139 patients with mild to moderate essential hypertension.
- Administration of bevantolol at fixed doses (200-400 mg/day) or placebo over eight weeks.
- Assessment of diastolic blood pressure reduction and efficacy at 12-hour post-dosing intervals.
Main Results:
- Bevantolol significantly lowered diastolic blood pressure at doses of 200 to 400 mg/day.
- Sustained blood pressure lowering effects were observed throughout the eight-week study period.
- Efficacy was evident 12 hours post-dosing, supporting twice-daily administration.
Conclusions:
- Bevantolol is an effective antihypertensive agent for mild to moderate essential hypertension.
- The drug is well-tolerated, suggesting a favorable safety profile.
- Twice-daily dosing of bevantolol is recommended for sustained blood pressure control.
Abstract:
This multicenter study, conducted to determine the antihypertensive efficacy of bevantolol at different fixed doses compared with placebo was carried out at four separate institutions using a common protocol. One hundred thirty-nine patients with mild to moderate essential hypertension were enrolled. At doses of 200 to 400 mg/day bevantolol was clearly effective in lowering diastolic blood pressure and in maintaining this effect over the eight weeks of this double-blind study. Twice a day dosing is indicated since efficacy was evident 12 hours post-dosing. Bevantolol was well tolerated.